In case studies and clinical trials, our products have been demonstrated to reduce infections and improve wellbeing in real-world settings.
This in vitro study characterised the efficacy of the Novaerus 1050 device at removing aerosolized MS2 Bacteriophage - a surrogate for influenza and coronaviruses - including Covid-19.
To evaluate the effect of implementing the NV200 devices on infection, staff sickness, and odour issues within the hospital wards and patient rooms and wards.
The Company believed making improvements to the work environment would improve performance and productivity, reduce employee absences and protect employees.
Mamos Delne looked to create a safe and healthy indoor environment for the children in their care.
As well as the standard protocols, Uzsoki Hospital deployed an additional layer of protection against COVID-19; air dis-infection technology by Novaerus.
The University wanted to improve the overall air quality in the geriatric and chronic disease wards.